Literature DB >> 1864921

A critical note on Lezak's 'best performance method' in clinical neuropsychology.

E L Mortensen1, A Gade, J M Reinisch.   

Abstract

A fundamental problem in clinical neuropsychology is the estimation of premorbid levels of cognitive functioning. Lezak (1983) described the so-called 'best performance method' of estimating premorbid abilities. Essentially, this method consists in using the highest test scores or the best performance in everyday tasks as the best estimate of premorbid ability. This paper describes three studies of the empirical consequences of using the 'best performance method': The first study demonstrates that application of this method on WAIS subtests leads to a gross overestimation of intelligence as measured by the IQ. The second study corroborates this finding and also shows that overestimation of intelligence leads to systematic errors in the expected performance in neuropsychological tests in normal subjects. Finally, the third study shows that this is also the case in patients with diffuse cerebral atrophy.

Entities:  

Mesh:

Year:  1991        PMID: 1864921     DOI: 10.1080/01688639108401050

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  3 in total

Review 1.  Forensic neuropsychology: the art of practicing a science that does not yet exist.

Authors:  D Faust
Journal:  Neuropsychol Rev       Date:  1991-09       Impact factor: 7.444

Review 2.  The Wechsler Memory Scale-Revised: psychometric characteristics and clinical application.

Authors:  R W Elwood
Journal:  Neuropsychol Rev       Date:  1991-06       Impact factor: 7.444

3.  Patient Characterization Protocols for Psychophysiological Studies of Traumatic Brain Injury and Post-TBI Psychiatric Disorders.

Authors:  Paul E Rapp; Brenna M Rosenberg; David O Keyser; Dominic Nathan; Kevin M Toruno; Christopher J Cellucci; Alfonso M Albano; Scott A Wylie; Douglas Gibson; Adele M K Gilpin; Theodore R Bashore
Journal:  Front Neurol       Date:  2013-07-22       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.